ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Other Events
Item 8.01
| Other Events |
On January 3, 2017 we issued a press release announcing that we
are exploring a range of financing and strategic alternatives,
including a possible sale of the company and that we retained
Roth Capital Partners LLC to assist in this process. A copy of
our press release is attached as Exhibit 99.1 hereto and is
incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number | Description |
| 99.1 | Press Release dated January 3, 2017 |
About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine. ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Recent Trading Information
ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) closed its last trading session down -0.065 at 0.775 with 63,139 shares trading hands.
